Clinical Trial Goal
To find out if BrECADD therapy is safe and works well to treat cHL that has not yet been treated
You may be able to join this trial if you:
- Are 18 - 60 years old
- Have cHL, stage 2b - 4, that has not yet been treated
- Do not have cHL stage 1 or 1a
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
BrECADD therapy is a combination of 6 drugs:
Brentuximab is a monoclonal antibody-drug conjugate that targets CD30 on certain cells.
Cyclophosphamide, dacarbazine, doxorubicin and etoposide are chemotherapy (chemo) drugs that block the growth of cancer cells.
Dexamethasone is a drug that reduces inflammation.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Brentuximab is a monoclonal antibody-drug conjugate that targets CD30 on certain cells.
Cyclophosphamide, dacarbazine, doxorubicin and etoposide are chemotherapy (chemo) drugs that block the growth of cancer cells.
Dexamethasone is a drug that reduces inflammation.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Brentuximab vedotin – Given as an intravenous (IV) infusion 1 time
- Cyclophosphamide – Given as an IV infusion 1 time
- Dacarbazine – Given as an IV infusion 1 time each day for 2 days
- Dexamethasone – A pill that you take by mouth 1 time each day for 4 days
- Doxorubicin – Given as an IV infusion 1 time
- Etoposide – Given as an IV infusion 1 time each day for 3 days
You may continue treatment for up to 2 years. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for about 3.5 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat cHL that has not yet been treated is new and unproven.
Contacts
Michele Stanchina, DO, +1 (305) 243-5302, mds331@med.miami.edu
Craig Moskowitz, MD, + 1 (305) 243-9009, chm78@miami.edu
Locations
University of MiamiRECRUITING
Miami, Florida
Michele Stanchina, DO, 1 (305) 243-5302, mds331@med.miami.edu
Sponsors
collaborator: Pfizer, lead: University of Miami
